MERZ on the Move: Days After Ulthera Acquisition, Company Announces Plans for New Retinoid Therapy
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Pivotal trial data showed sustained improvement in chin projection and high patient and investigator satisfaction through 12 months.